Cystatin C test ups risk prediction

An international study has found cystatin C testing dramatically improves risk prediction.

The meta-analysis of 11 general population studies and five chronic kidney disease studies showed that when using cystatin C to measure estimated glomerular filtration rate (eGFR), reclassifying patients to an eGFR rate above 60 reduced their risk of death by 34%, and reclassifying to an eGFR of less than 60 increased their risk of death by 67%.

The risk of death from any cause was increased at cystatin C